Welcome to our dedicated page for APIMEDS PHARMACEUTICALS US SEC filings (Ticker: APUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) provides access to the company’s regulatory disclosures as an Exchange Act registrant with common stock listed on the NYSE American. These filings document key aspects of Apimeds’ evolution as a clinical-stage biopharmaceutical company focused on non-opioid, biologic-based pain therapies and its merger with MindWave Innovations Inc., an institutional Digital Asset Treasury solutions provider.
Among the most informative documents are the company’s current reports on Form 8-K, which describe material events such as the entry into an Agreement and Plan of Merger with MindWave Innovations Inc., Apimeds Merger Sub, Inc., and Lokahi Therapeutics, Inc.; the structure of the merger consideration, including common and preferred stock; and the resulting ownership percentages. Other 8-K filings detail amendments to bylaws to allow shareholder action by written consent, changes to executive employment agreements, and departures or removals of directors, along with the composition of the remaining board.
Filings also address capital structure and financing arrangements, including a Securities Purchase Agreement for senior convertible notes, amendments to that agreement, and a certificate of designation for Series A Convertible Preferred Stock. An amended Form 8-K (8-K/A) explains corrections to the merger agreement and to the number of preferred shares designated, illustrating how Apimeds uses SEC filings to clarify and update previously reported terms.
Investors reviewing APUS filings can trace the company’s initial public offering on the NYSE American, its status as an emerging growth company, and subsequent PIPE financing associated with the MindWave merger, as described across registration statements and current reports. The filings also reference the preparation of an Information Statement under Section 14(c) of the Exchange Act to describe the merger, related stockholder approvals, reverse stock split, and equity incentive plan changes.
On Stock Titan, these SEC documents are supplemented by AI-powered summaries that highlight the main points of lengthy filings, such as 8-Ks and related exhibits. Users can quickly understand how each filing relates to Apimeds’ Apitox development program, its non-opioid pain-management focus, its integration of digital-asset treasury capabilities, and its governance and capital structure decisions, without reading every page in full.
Apimeds Pharmaceuticals US, Inc. has completed a reverse merger with MindWave Innovations Inc., making MindWave a wholly owned subsidiary and giving former MindWave stockholders, on an as-converted and fully diluted basis, 90.9% of the company’s equity through a mix of common and preferred stock.
Certain majority stockholders have already approved by written consent several key actions: conversion of Series A preferred stock into common shares, conversion of sizable senior convertible notes issued under a Securities Purchase Agreement, a potential 1-for-10 reverse stock split with a par value reduction from $0.01 to $0.001, an increase in the 2024 equity plan to 2,096,679 issuable shares, and adoption of a new 2025 equity plan. The board may still choose whether or not to implement the reverse split.
The company also describes a senior convertible note financing of up to $120,900,000 at an 8% original issue discount, with an initial tranche made available at closing and additional funding tied to effectiveness of a resale registration statement and investor elections. Existing common stockholders keep their current shares but will sit alongside a new controlling stockholder base and significant convertible securities once the actions become effective.
Apimeds Pharmaceuticals US, Inc. reported a change in its board of directors. On December 30, 2025, stockholders acting by written consent removed Erik Emerson from the company’s board, effective the same day. The action was approved by stockholders holding a majority of the outstanding common stock voting power entitled to vote in director elections, in line with the company’s organizational documents and applicable law. The filing states that other individuals remain on the board of directors, though they are not named here.
Apimeds Pharmaceuticals US, Inc. reported that on December 5, 2025, two members of its Board of Directors resigned. Director Dr. Vin Menon and Independent Director Amir A. Dossal both stepped down from their board positions.
The company stated that these resignations were not due to any disagreement regarding its operations, policies, or practices. Dr. Menon continues to serve as Chief Executive Officer, as he signed the report in that capacity. The filing focuses solely on this board-level leadership change and does not include financial results or transaction details.
Apimeds Pharmaceuticals US, Inc. filed an amended current report to correct drafting mistakes in its previously disclosed MindWave Innovations merger and related preferred stock designation. The Merger Agreement is revised to remove provisions that had incorrectly given MindWave the right to appoint directors, to set the Common Stock Cap at 0% of Apimeds common shares, and to state that Series A preferred stock issued to existing MindWave holders will represent 90.9% of Apimeds’ fully diluted equity. The company also corrects its Certificate of Designation so that 7,477,017 shares of Series A Convertible Preferred Stock are designated, instead of 7,263,865. In addition, Apimeds discloses Amendment No. 1 to a Securities Purchase Agreement covering up to $120,900,000 of senior convertible notes, clarifying variable-rate transaction restrictions, expanding investor notification rights for other funding events, and extending the deadline for the Initial Closing.
Apimeds Pharmaceuticals US, Inc. completed a reverse merger with MindWave Innovations Inc., making MindWave a wholly owned subsidiary and effecting a change in control. MindWave stockholders received a mix of Apimeds common and new non‑voting Series A preferred shares so that, on an as‑converted, fully diluted basis, they hold 61% of Apimeds’ equity (excluding certain new common) and, together with common issued at closing, control 90.9% of Apimeds’ equity capital as of closing.
Apimeds entered into an up to $120.9M senior unsecured convertible note facility with an 8% original issue discount, with $10.875M available at closing and another $2.175M upon effectiveness of a resale Form S‑1. The notes are convertible at 80% of the lowest five‑day VWAP, subject to monthly volume limits, and mature 12 months after issuance. The company also issued 7,263,865 Series A preferred shares, each automatically convertible into 20 common shares after stockholder and NYSE American approvals and a planned 1‑for‑10 reverse stock split, and granted a warrant for 712,880 common shares to E.F. Hutton.
Apimeds Pharmaceuticals US, Inc. (APUS) filed an amended Form 4 to correct how an insider’s holdings are reported. The filing shows that 4,316,618 shares of common stock are held indirectly through Apimeds Inc. (“Apimeds Korea”), a wholly owned subsidiary of the reporting person.
The amendment explains that earlier filings incorrectly showed a Convertible Promissory Note of $184,833 and the related common shares as indirectly owned through Apimeds Korea. As of May 12, 2025, the reporting person had direct beneficial ownership of 2,099,747 common shares and indirect beneficial ownership of 4,316,618 common shares held by Apimeds Korea. The insider also disclaims beneficial ownership of the subsidiary-held shares for certain legal purposes.
Apimeds Pharmaceuticals US, Inc. updated the employment terms of its Chief Executive Officer, Erik Emerson. Effective November 13, 2025, the company increased the CEO’s annual base salary to $500,000. The amendment also enhances protection for the CEO if he is terminated by the company without cause, granting a severance payment equal to 24 months of base salary and benefits, along with immediate vesting of all unvested equity, subject to his signing a release of claims. If he is terminated for cause, or resigns without good reason, any unvested equity will be automatically forfeited without payment or additional consideration.
Apimeds Pharmaceuticals US, Inc. (APUS) — Form 4 insider activity: A director reported the grant of a stock option for 10,000 shares with an exercise price of $2.67 per share on 11/11/2025. The option expires on 11/11/2035 and was reported as directly owned.
The award vests in quarterly installments beginning October 1, 2025, becoming fully vested after three years. The option is not exercisable until stockholder approval is obtained to amend the company’s incentive plan to increase available shares. The award will vest in full upon a Change in Control as defined in the plan.
Apimeds Pharmaceuticals US, Inc. (APUS) reported a director’s stock option grant. On 11/11/2025, the reporting person received an option to buy 10,000 shares of common stock at an exercise price of $2.67 per share, expiring on 11/11/2035. The award was coded as an acquisition and priced at $0 for the derivative grant, with 10,000 derivative securities beneficially owned directly after the transaction.
The option vests in quarterly installments beginning October 1, 2025 over three years and becomes exercisable only after stockholder approval of an amendment to increase shares available under the incentive plan. It vests in full upon a Change in Control as defined in the plan.